MDxHealth
Prostate diagnostics company that bought Oncotype DX GPS from Exact Sciences and sells the Select mdx and Confirm mdx tests.
Overview
MDxHealth's portfolio spans the pre-biopsy urine test Select mdx, the post-negative-biopsy methylation test Confirm mdx, the Genomic Prostate Score acquired in 2022, and Resolve mdx for urinary tract infections; it moved its headquarters from Belgium to California in 2023.
Scorecard
All companies- modalities +2
Pages like this
not linked directly; found by shared links- TermGleason score / Grade Group
Shares Oncotype DX Genomic Prostate Score, Active surveillance, Prostate cancer.
- ProductDecipher Prostate
Shares Oncotype DX Genomic Prostate Score, Active surveillance, Prostate cancer.
- ProductPadeliporfin
Shares Active surveillance, Prostate cancer.
- ProductProlaris
Shares Oncotype DX Genomic Prostate Score, Active surveillance, Prostate cancer.
- TermActive surveillance and observation
Shares Oncotype DX Genomic Prostate Score, Active surveillance, Prostate cancer.
- TechnologyMultiparametric prostate MRI (PI-RADS)
Shares Active surveillance, Prostate cancer.
- TermGleason score and Grade Group
Shares Active surveillance, Prostate cancer.
- TrialProtecT
Shares Active surveillance, Prostate cancer.